Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monofer for postoperative iron deficiency anemia after spinal metastasis surgery
ChiCTR2300074150Phase 4Not yet recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Aug 2023
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ferric derisomaltose in iron deficiency anemia (IDA) (2 arms), sponsored by Shanghai Changzheng Hospital. Primary endpoint: Hemoglobin at Day 28. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on ChiCTR2300074150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074150.